The National Cancer Institute’s Investigational New Drug program facilitates collaboration, not collusion, with industry for ...

In a landmark decision poised to revolutionize drug development, the U.S. Food and Drug Administration (FDA) has announced a ...

AXS-12, known as reboxetine back when it was available as an antidepressant in the United States, may decrease cataplexy ...

AI-driven drug discovery firms rallied on Friday after the U.S. Food and Drug Administration (FDA) announced an initiative to ...

The FDA has announced plans to phase out animal testing in the development of monoclonal antibodies and other drugs.

Epicrispr Biotechnologies Announces FDA Clearance of IND Application for EPI-321, A First-in-Class Epigenetic Therapy for ...

The FDA will begin replacing animal testing in the development of monoclonal antibody therapies and other drugs with ...

The initiative, which will start with monoclonal antibodies, is the first big regulatory shift from the FDA since Martin ...

today announced that the U.S. Food and Drug Administration (FDA) has cleared Altesa's new Investigational New Drug (IND) application for vapendavir for the treatment of rhinovirus infections in ...

The FDA laid out a three-year roadmap to phase out animal toxicity testing in drug research. In addition to organoids and lab ...

Highlights from the oral presentation include: New efficacy findings consistently demonstrated rapid recovery and durable benefits of tanruprubart across muscle strength, mobility, and disability ...